BioNTech: Latest News

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Also Read: Death due to COVID-19 vaccine: 28-year-old dies after jab; family to get ₹1.4 crore Moderna previously said it was considering pricing its COVID vaccine in a range of $110 to $130 per dose in the United States, similar to the range Pfizer Inc said in October it was considering for its rival COVID shots sold in partnership with BioNTech. Also Read: Covid vaccine: India saved over 3.4 million lives under nationwide vaccine campaign: Report Hoge said the government's Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine.

COVID-19 vaccine "safety signal" has been identified and is investigating whether the Bivalent Pfizer-BioNTech vaccine creates an increased risk of ischemic stroke in people 65 and older.In the statement, the CDC says that the preliminary signal hasn't been identified with Bivalent Moderna COVID-19 vaccine."Following the availability and use of the updated (bivalent) COVID-19 vaccines, CDC’s Vaccine Safety Datalink (VSD), a near real-time surveillance system, met the statistical criteria to prompt additional investigation into whether there was a safety concern for ischemic stroke in people ages 65 and older who received the Pfizer-BioNTech COVID-19 Vaccine, Bivalent." "Rapid-response investigation of the signal in the VSD raised a question of whether people 65 and older who have received the Pfizer-BioNTech COVID-19 Vaccine, Bivalent were more likely to have an ischemic stroke in the 21 days following vaccination compared with days 22-44 following vaccination," the CDC said in a statement Friday. FILE - A doctor vaccinates a woman with the new COVID-19 booster from the Pfizer-Biontech company.

FRANKFURT :

This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

LOS ANGELES - On Tuesday, Pfizer and BioNTech announced they have submitted a request for emergency use authorization from the U.S. Food and Drug Administration for a COVID-19 vaccine booster for all U.S.